Parkinson's disease (PD) affects >1M people in the EU, and is a source of significant suffering and costs to the Community. Unlike available medical therapy, restoration of function has been demonstrated in patients receiving fatal grafts containing developing dopaminergic cells. Unfortunately, large-scale cell replacement therapy for PD is not feasible using primary human fatal tissues for both practical and ethical issues. In this proposal, we present a plan to develop expandable human dopaminergic neuronal cell lines capable of transplanting large numbers of PD patients. To achieve this goal, we will use human neural precursor cells and state-of-the-art molecular tools combined with a multidisciplinary team consisting of 4 academic and one industrial partner. At the end of the proposed work period, a cell line suitable for clinical trials in PD is anticipated.
Funding SchemeCSC - Cost-sharing contracts
171 77 Stockholm
221 00 Lund